Alterity Therapeutics Limited

ATHE | NASDAQ

Price Alert Chart Builder DCF Calculator

$3.91

+$0.13 (+3.44%)

Sep 22, 2026, 2:15 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+3.44%

(1D)

Rating

Updated: Aug 26, 2026

28.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $66.24M

1D Range

3.77 4

52W Range

2.66 5.89

Valuation (TTM)

PE -4.32

PB 2.22

EV/EBITDA -2.04

Valuation (NTM)

Forward PE N/A

Forward PEG -0.13

Price Target $8

Cash Flow

FCF Yield 0.0%

SBC Adj. FCF Yield 0.0%

SBC Impact N/A

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y -84.1% | -9.1%

Dil EPS 3Y | 5Y 38.4% | 43.4%

FCF 3Y | 5Y 61.5% | 12.0%

Returns

ROA -50.9%

ROE -48.3%

ROIC -57.6%

Financial Health

Net Cash

A$37.26M ($25.78M)

Current Ratio 14.52

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntingt...

Sector Healthcare

Industry Biotechnology

Employees 11

IPO Date Sep 28, 2003

Website alteritytherapeutics.com

Fiscal Year July - June

Full Company Profile

Latest News

No news articles available yet.

Earnings

Latest Earnings

Aug 28, 2026

EPS

-$0.05

Beat +57.47%

YoY: +85.31%

REV

$806.59K

Miss -65.24%

YoY: -80.52%

Next Earnings

Mar 4, 2027

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞